Kisunla™

Kisunla™ (donanemab-azbt) is a groundbreaking treatment developed by Eli Lilly and Company for individuals in the early stages of Alzheimer’s disease, aiming to provide patients and their families with more time to engage in meaningful activities and maintain their independence.